How big is C4 Therapeutics, Inc.?

As of Jun 18, C4 Therapeutics, Inc. has a market capitalization of 105.80 million and reported net sales of 39.79 million with a net profit loss of 103.28 million for the latest four quarters ending in March 2025.

Market Cap: As of Jun 18, C4 Therapeutics, Inc. has a market capitalization of 105.80 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, C4 Therapeutics, Inc. reported net sales of 39.79 million. However, the company experienced a net profit loss of 103.28 million during the same period.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds amounted to 215.99 million, while total assets were reported at 349.60 million.

What does C4 Therapeutics, Inc. do?

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that target and eliminate disease-causing proteins, primarily in cancer and neurodegenerative diseases. As of March 2025, it has a market cap of $105.80 million, with net sales of $7 million and a net loss of $26 million.

Overview: <BR>C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic candidates that target and destroy disease-causing proteins, primarily in the cancer and neurodegenerative disease sectors, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 105.80 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.07 <BR>Return on Equity: -52.92% <BR>Price to Book: 0.54<BR><BR>Contact Details: <BR>Address: 490 Arsenal Way, Suite 200, WATERTOWN MA: 02472 <BR>Tel: 1 617 2310700 <BR>Fax: 1 302 6555049 <BR>Website: http://www.c4thera.com/

Should I buy, sell or hold C4 Therapeutics, Inc.?

Who are in the management team of C4 Therapeutics, Inc.?

As of March 2022, the management team of C4 Therapeutics, Inc. includes Executive Chairman and Co-Founder Marc Cohen, President and CEO Andrew Hirsch, and Co-Founder and Director Ken Anderson.

As of March 2022, the management team of C4 Therapeutics, Inc. includes Mr. Marc Cohen, who serves as the Executive Chairman of the Board and is a Co-Founder of the company. Mr. Andrew Hirsch is the President, Chief Executive Officer, and a Director. Additionally, Mr. Ken Anderson is a Co-Founder and serves as a Director.

Is C4 Therapeutics, Inc. technically bullish or bearish?

As of June 2, 2025, C4 Therapeutics, Inc. is in a mildly bearish trend, indicated by daily moving averages and weekly Bollinger Bands, despite some mixed signals from the MACD and KST indicators.

As of 2 June 2025, the technical trend for C4 Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. While the MACD on both weekly and monthly time frames is mildly bullish, the KST monthly indicator is bearish, suggesting mixed signals. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the indicators reflect a weak bearish sentiment with some bullish signs on longer time frames, but the prevailing trend remains mildly bearish.